Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma

NCT01460940 is registered in ClinicalTrials.gov with Ohio State University Comprehensive Cancer Center as lead sponsor.

NCT NCT01460940
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01460940 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Lead sponsor
Ohio State University Comprehensive Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
October 13, 2011
Completion date
November 16, 2016
Enrollment
24 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

adult lymphocyte depletion hodgkin lymphoma, adult lymphocyte predominant hodgkin lymphoma, adult mixed cellularity hodgkin lymphoma, adult nodular lymphocyte predominant hodgkin lymphoma, adult nodular sclerosis hodgkin lymphoma, recurrent adult hodgkin lymphoma